Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
CAR T cell
Costs
Healthcare resource utilization
Idecabtagene vicleucel
Multiple myeloma
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
07
04
2023
accepted:
19
07
2023
medline:
14
9
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable responses in patients with RRMM in the pivotal phase 2 KarMMa trial (NCT03361748). Healthcare resource utilization (HCRU) and costs were estimated for ide-cel-treated patients in the KarMMa trial. Post-infusion costs were estimated based on HCRU data, including facility care, diagnostics, medications, and procedures. Length of stay (LOS) was extracted for inpatient and intensive care unit (ICU) care. All patients had a 14-day post-infusion inpatient stay per trial protocol. Analyses were conducted for patients treated in the United States (US), who received the ide-cel target dose of 450 × 10 Overall, 128 patients received ide-cel and were included in this analysis. Mean age was 60 years, 59% were men, and 81% were white. Mean total LOS was 23.9 days. Total estimated costs over 24 months post-infusion were US$115,614 per patient, driven by facility costs (75%; $86,385). Most costs were incurred in the first month (58%; $67,259). The scenario analysis assuming a 7-day inpatient stay showed estimated 24-month costs of $92,294. For the 54 (42%) patients who received ide-cel high dose, total costs over 24 months were $113,298 per patient. Extrapolation of costs based on HCRU data from patients receiving single-infusion of ide-cel in the KarMMa trial showed substantially reduced HCRU and costs over 2 years after initial treatment. Most costs were incurred during the first month after ide-cel infusion, likely attributable to the 14-day inpatient stay required by the trial protocol. These findings suggest a nominal, incremental monthly cost of care immediately after treatment, which may be lower in routine clinical practice.
Identifiants
pubmed: 37597153
doi: 10.1007/s12325-023-02623-w
pii: 10.1007/s12325-023-02623-w
pmc: PMC10499666
doi:
Substances chimiques
idecabtagene vicleucel
8PX1X7UG4D
Receptors, Chimeric Antigen
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4626-4638Informations de copyright
© 2023. The Author(s).
Références
Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/jama.2022.0003 . (PMID: 35103762).
doi: 10.1001/jama.2022.0003
pubmed: 35103762
Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):52–61. https://doi.org/10.1093/annonc/mdx096 . (PMID: 28453614).
doi: 10.1093/annonc/mdx096
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer Statistics Explorer Network; Apr 19, 2023. [updated Jun 8, 2023]. https://seer.cancer.gov/statistics-network/explorer/application.html?site=89&data_type=9&graph_type=2&compareBy=rate_type&chk_rate_type_1=1&chk_rate_type_2=2&chk_rate_type_3=3&sex=1&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0 . Accessed June 16, 2023.
Lee HC, Ramasamy K, Weisel K, et al. Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the connect MM disease registry. Clin Lymphoma Myeloma Leuk. 2023;23(2):112–22. https://doi.org/10.1016/j.clml.2022.11.008 . (PMID: 36567211).
doi: 10.1016/j.clml.2022.11.008
pubmed: 36567211
Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78:19–37. https://doi.org/10.1007/s40265-017-0841-y .
doi: 10.1007/s40265-017-0841-y
pubmed: 29188449
Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–92. https://doi.org/10.1038/leu.2013.293 . (PMID: 24177258).
doi: 10.1038/leu.2013.293
pubmed: 24177258
Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma. Future Oncol. 2023;19(11):775–87. https://doi.org/10.2217/fon-2022-1018 .
doi: 10.2217/fon-2022-1018
pubmed: 37132520
Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75. https://doi.org/10.1038/s41375-019-0435-7 .
doi: 10.1038/s41375-019-0435-7
pubmed: 30858549
pmcid: 6820050
Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8. https://doi.org/10.1038/leu.2017.138 .
doi: 10.1038/leu.2017.138
pubmed: 28620163
Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1–7. https://doi.org/10.1016/j.clml.2019.09.621 .
doi: 10.1016/j.clml.2019.09.621
pubmed: 31767529
Afram G, Gran C, Borg Bruchfeld J, et al. Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: real-life outcomes of daratumumab treatment. Eur J Haematol. 2020;105(2):196–202. https://doi.org/10.1111/ejh.13426 .
doi: 10.1111/ejh.13426
pubmed: 32281193
Despiegel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19:e13-28. https://doi.org/10.1016/j.clml.2018.08.019 .
doi: 10.1016/j.clml.2018.08.019
pubmed: 30292736
Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with “symptomatic” relapsed or refractory multiple myeloma. Support Care Cancer. 2021;29:467–75. https://doi.org/10.1007/s00520-020-05493-y .
doi: 10.1007/s00520-020-05493-y
pubmed: 32390093
Jagannath S, Joseph N, He J, et al. Healthcare costs incurred by patients with multiple myeloma following triple class exposure (TCE) in the US. Oncol Ther. 2021;9:659–69. https://doi.org/10.1007/s40487-021-00175-z .
doi: 10.1007/s40487-021-00175-z
pubmed: 34694578
pmcid: 8593112
Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17:503–15. https://doi.org/10.2217/fon-2020-1003 .
doi: 10.2217/fon-2020-1003
pubmed: 33522834
European Medicines - Medicines Agency. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharma EEIG. August 2021. https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf . Accessed June 16, 2023.
Bristol Myers Squibb. ABECMA (idecabtagene vicleucel). [Prescribing information]. https://packageinserts.bms.com/pi/pi_abecma.pdf . Accessed February 3. 2023.
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850 .
doi: 10.1056/NEJMoa2024850
pubmed: 33626253
National Institutes of Health. ClinicalTrials.gov. Efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma (KarMMa). [Published 3 Dec 2017]. [Updated 9 Mar 2023]. https://clinicaltrials.gov/ct2/show/NCT03361748 . Accessed June 16, 2023.
Bristol Myers Squibb. Bristol-Myers Squibb and bluebird bio announce positive top-line results from the pivotal phase 2 KarMMa study of ide-cel in relapsed and refractory multiple myeloma [press release]; 2019. https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-and-bluebird-bio-Announce-Positive-Top-line-Results-from-the-Pivotal-Phase-2-KarMMa-Study-of-Ide-cel-in-Relapsed-and-Refractory-Multiple-Myeloma/default.aspx . Accessed February 3, 2023.
Anderson LD, Munshi NC, Shah N, et al. OAB-027: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR-T cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S17–8.
Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6:1309–18. https://doi.org/10.1182/bloodadvances.2021005913 .
doi: 10.1182/bloodadvances.2021005913
pubmed: 34933328
pmcid: 8864645
Hari P, Nguyen A, Pelletier C, et al. PCN58 Estimation of post-infusion costs of care for patients with relapsed or refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial. Value Health. 2021;24(Suppl 1):S29-30. https://doi.org/10.1016/j.jval.2021.04.150 .
doi: 10.1016/j.jval.2021.04.150
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6 .
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Xu X, Lazar CM, Ruger JP. Micro-costing in health and medicine: a critical appraisal. Health Econ Rev. 2021;11(1):1. https://doi.org/10.1186/s13561-020-00298-5 . (PMID: 33404857; PMCID: PMC7789519).
doi: 10.1186/s13561-020-00298-5
pubmed: 33404857
pmcid: 7789519
Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33:1266–71. https://doi.org/10.1097/01.ccm.0000164543.14619.00 .
doi: 10.1097/01.ccm.0000164543.14619.00
pubmed: 15942342
Leavitt Partners. Cancer treatment costs are consistently lower in the community setting versus the hospital outpatient department [white paper]; 2017. https://leavittpartners.com/whitepaper/cancer-treatment-costs-are-consistently-lower-in-the-community-setting-versus-the-hospital-outpatient-department/ . Accessed February 3, 2023.
Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 1998;21:927–32. https://doi.org/10.1038/sj.bmt.1701191 .
doi: 10.1038/sj.bmt.1701191
pubmed: 9613786
Ghanem B, Shi L. The economic burden of CAR T cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US. BioDrugs. 2022;36:773–80. https://doi.org/10.1007/s40259-022-00557-3 .
doi: 10.1007/s40259-022-00557-3
pubmed: 36167952